The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI

PHASE4CompletedINTERVENTIONAL
Enrollment

818

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

October 31, 2019

Study Completion Date

January 31, 2020

Conditions
Acute ST Elevation Myocardial Infarction
Interventions
DRUG

rhTNK-tPA

Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.

DRUG

alteplase

Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.

Trial Locations (1)

510530

Guangzhou Recomgen Biotech Co., Ltd., Guangzhou

All Listed Sponsors
collaborator

Chinese Academy of Medical Sciences, Fuwai Hospital

OTHER

collaborator

Peking University

OTHER

lead

CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.

INDUSTRY

NCT02835534 - The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI | Biotech Hunter | Biotech Hunter